Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin: 2010-2024

Historic EBITDA Margin for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -107.50%.

  • China Pharma Holdings' EBITDA Margin rose 1054.00% to -78.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -81.63%, marking a year-over-year increase of 39.00%. This contributed to the annual value of -107.50% for FY2024, which is 6187.00% down from last year.
  • Per China Pharma Holdings' latest filing, its EBITDA Margin stood at -107.50% for FY2024, which was down 135.56% from -45.64% recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' EBITDA Margin registered a high of -19.30% during FY2020, and its lowest value of -107.50% during FY2024.
  • Moreover, its 3-year median value for EBITDA Margin was -61.25% (2022), whereas its average is -71.46%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 16,784bps in 2020, then crashed by 6,187bps in 2024.
  • Over the past 5 years, China Pharma Holdings' EBITDA Margin (Yearly) stood at -19.30% in 2020, then crashed by 1,369bps to -32.99% in 2021, then slumped by 2,826bps to -61.25% in 2022, then skyrocketed by 1,561bps to -45.64% in 2023, then tumbled by 6,187bps to -107.50% in 2024.